Esophageal Cancer - Pipeline Review, H1 2017

Published: Apr, 2017 | Pages: 493 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer - Pipeline Review, H1 2017, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 33, 28, 2, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 5, 2 and 1 molecules, respectively.

Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 9
Global Markets Direct Report Coverage 9
Esophageal Cancer - Overview 10
Esophageal Cancer - Therapeutics Development 11
Pipeline Overview 11
Pipeline by Companies 12
Pipeline by Universities/Institutes 17
Products under Development by Companies 18
Products under Development by Universities/Institutes 23
Esophageal Cancer - Therapeutics Assessment 24
Assessment by Target 24
Assessment by Mechanism of Action 28
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Esophageal Cancer - Companies Involved in Therapeutics Development 36
Adaptimmune Therapeutics Plc 36
ADC Therapeutics Sarl 36
Aduro BioTech Inc 37
Advaxis Inc 37
Advenchen Laboratories LLC 38
Almac Discovery Ltd 38
Amgen Inc 39
Aprea AB 39
ArQule Inc 40
Array BioPharma Inc 40
Aslan Pharmaceuticals Pte Ltd 41
ATLAB Pharma SAS 41
Bayer AG 42
BeiGene Ltd 42
Beta Pharma Inc 43
Boehringer Ingelheim GmbH 43
Bristol-Myers Squibb Company 44
CBT Pharmaceuticals Inc 44
Celgene Corp 45
Celldex Therapeutics Inc 45
Cellectar Biosciences Inc 46
CellSeed Inc 46
Clovis Oncology Inc 47
Cyclacel Pharmaceuticals Inc 47
Eli Lilly and Company 48
F. Hoffmann-La Roche Ltd 48
Genmab A/S 49
GlaxoSmithKline Plc 49
Glycotope GmbH 50
Hutchison China MediTech Ltd 50
Ignyta Inc 51
Immunocore Ltd 51
ImmunoFrontier Inc 52
Immunomedics Inc 52
Intezyne Technologies Inc 53
Jiangsu Hengrui Medicine Co Ltd 53
Johnson & Johnson 54
Komipharm International Co Ltd 54
Leap Therapeutics Inc 55
MaxiVAX SA 55
Mebiopharm Co Ltd 56
MedImmune LLC 56
Merck & Co Inc 57
Novartis AG 57
Omeros Corp 58
Oncolys BioPharma Inc 58
OncoMed Pharmaceuticals Inc 59
Ono Pharmaceutical Co Ltd 60
Puma Biotechnology Inc 60
Rhizen Pharmaceuticals SA 61
Shionogi & Co Ltd 61
Spectrum Pharmaceuticals Inc 62
Stelic Institute & Co Inc 62
Supratek Pharma Inc 63
Symphogen A/S 63
Taiho Pharmaceutical Co Ltd 64
Taiwan Liposome Company Ltd 64
Takara Bio Inc 65
Transgene Biotek Ltd 65
VioQuest Pharmaceuticals Inc 66
XuanZhu Pharma Co Ltd 66
Esophageal Cancer - Drug Profiles 67
(tipiracil hydrochloride + trifluridine) - Drug Profile 67
1-BB1 - Drug Profile 73
ADCT-502 - Drug Profile 74
ADXS-HER2 - Drug Profile 75
afatinib dimaleate - Drug Profile 79
AL-3818 - Drug Profile 93
ALM-301 - Drug Profile 96
apatinib - Drug Profile 97
APR-246 - Drug Profile 101
atezolizumab - Drug Profile 105
ATL-101 - Drug Profile 122
BGBA-317 - Drug Profile 125
binimetinib - Drug Profile 127
brontictuzumab - Drug Profile 135
CBT-501 - Drug Profile 139
CDX-1401 - Drug Profile 141
Cellular Immunotherapy 1 for Esophageal Cancer - Drug Profile 144
Cellular Immunotherapy for Esophageal Cancer - Drug Profile 145
Cellular Immunotherapy for Oncology - Drug Profile 146
Cellular Immunotherapy for Oncology - Drug Profile 147
Cellular Immunotherapy for Oncology - Drug Profile 148
Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile 150
Cellular Immunotherapy to Target EPCAM for Oncology - Drug Profile 151
Cellular Immunotherapy to Target HER-2 for Advanced Malignancy and Metastatic Cancer - Drug Profile 152
Cellular Immunotherapy to Target MAGEA4 for Oncology - Drug Profile 153
Cellular Immunotherapy to Target NY-ESO 1 for Oncology - Drug Profile 155
cetuximab biobetter - Drug Profile 156
CGX-1321 - Drug Profile 158
CLS-2702C - Drug Profile 159
CRS-207 - Drug Profile 160
CYC-140 - Drug Profile 167
DKN-01 - Drug Profile 169
donafenib - Drug Profile 172
doxorubicin - Drug Profile 173
durvalumab - Drug Profile 174
elgemtumab - Drug Profile 188
erdafitinib - Drug Profile 190
futuximab + modotuximab - Drug Profile 192
ganetespib - Drug Profile 196
GSK-2256098 - Drug Profile 209
GSK-3359609 - Drug Profile 211
GSK-3377794 - Drug Profile 212
HKT-288 - Drug Profile 220
HMPL-309 - Drug Profile 221
I131-CLR1404 - Drug Profile 222
IBI-308 - Drug Profile 229
icotinib hydrochloride - Drug Profile 230
IMF-001 - Drug Profile 232
ipilimumab + nivolumab - Drug Profile 233
IT-139 - Drug Profile 238
JNJ-63723283 - Drug Profile 240
JS-001 - Drug Profile 241
KML-001 - Drug Profile 242
LY-3143921 - Drug Profile 244
MEDI-3622 - Drug Profile 245
Monoclonal Antibodies to Inhibit PD-L2 for Esophageal Cancer - Drug Profile 246
MVXONCO-1 - Drug Profile 247
neratinib - Drug Profile 249
nimotuzumab - Drug Profile 267
nintedanib - Drug Profile 271
nivolumab - Drug Profile 282
OBP-301 - Drug Profile 322
oxaliplatin - Drug Profile 324
paclitaxel albumin bound - Drug Profile 325
panitumumab - Drug Profile 337
pasireotide ER - Drug Profile 343
PCA-062 - Drug Profile 347
pembrolizumab - Drug Profile 348
pralatrexate - Drug Profile 394
Recombinant Protein 1 for Oncology - Drug Profile 400
rucaparib camsylate - Drug Profile 401
RXDX-106 - Drug Profile 410
S-222611 - Drug Profile 412
S-588410 - Drug Profile 414
sacituzumab - Drug Profile 416
SDS-eCAR - Drug Profile 427
SHR-1210 - Drug Profile 428
sirotinib - Drug Profile 430
Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile 431
Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile 432
SMYD2-BAY02 - Drug Profile 433
STNM-01 - Drug Profile 434
TBI-1201 - Drug Profile 436
TBL-0805E - Drug Profile 438
TGR-1202 - Drug Profile 439
tisotumab vedotin - Drug Profile 448
tivantinib - Drug Profile 450
TLC-388 - Drug Profile 456
triciribine phosphate - Drug Profile 458
Vaccine for Advanced Squamous Cell Carcinoma of Esophagus and Adenocarcinoma of Colon - Drug Profile 462
Vaccine for Oncology - Drug Profile 463
Vaccine for Oncology - Drug Profile 464
varlitinib - Drug Profile 465
VIMO-001 - Drug Profile 468
YQ-23 - Drug Profile 469
Esophageal Cancer - Dormant Projects 470
Esophageal Cancer - Discontinued Products 473
Esophageal Cancer - Product Development Milestones 474
Featured News & Press Releases 474
Appendix 486
Methodology 486
Coverage 486
Secondary Research 486
Primary Research 486
Expert Panel Validation 486
Contact Us 486
Disclaimer 487

List of Tables

Number of Products under Development for Esophageal Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
Esophageal Cancer - Pipeline by ADC Therapeutics Sarl, H1 2017
Esophageal Cancer - Pipeline by Aduro BioTech Inc, H1 2017
Esophageal Cancer - Pipeline by Advaxis Inc, H1 2017
Esophageal Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
Esophageal Cancer - Pipeline by Almac Discovery Ltd, H1 2017
Esophageal Cancer - Pipeline by Amgen Inc, H1 2017
Esophageal Cancer - Pipeline by Aprea AB, H1 2017
Esophageal Cancer - Pipeline by ArQule Inc, H1 2017
Esophageal Cancer - Pipeline by Array BioPharma Inc, H1 2017
Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017
Esophageal Cancer - Pipeline by ATLAB Pharma SAS, H1 2017
Esophageal Cancer - Pipeline by Bayer AG, H1 2017
Esophageal Cancer - Pipeline by BeiGene Ltd, H1 2017
Esophageal Cancer - Pipeline by Beta Pharma Inc, H1 2017
Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Esophageal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
Esophageal Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
Esophageal Cancer - Pipeline by Celgene Corp, H1 2017
Esophageal Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
Esophageal Cancer - Pipeline by Cellectar Biosciences Inc, H1 2017
Esophageal Cancer - Pipeline by CellSeed Inc, H1 2017
Esophageal Cancer - Pipeline by Clovis Oncology Inc, H1 2017
Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
Esophageal Cancer - Pipeline by Eli Lilly and Company, H1 2017
Esophageal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Esophageal Cancer - Pipeline by Genmab A/S, H1 2017
Esophageal Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
Esophageal Cancer - Pipeline by Glycotope GmbH, H1 2017
Esophageal Cancer - Pipeline by Hutchison China MediTech Ltd, H1 2017
Esophageal Cancer - Pipeline by Ignyta Inc, H1 2017
Esophageal Cancer - Pipeline by Immunocore Ltd, H1 2017
Esophageal Cancer - Pipeline by ImmunoFrontier Inc, H1 2017
Esophageal Cancer - Pipeline by Immunomedics Inc, H1 2017
Esophageal Cancer - Pipeline by Intezyne Technologies Inc, H1 2017
Esophageal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Esophageal Cancer - Pipeline by Johnson & Johnson, H1 2017
Esophageal Cancer - Pipeline by Komipharm International Co Ltd, H1 2017
Esophageal Cancer - Pipeline by Leap Therapeutics Inc, H1 2017
Esophageal Cancer - Pipeline by MaxiVAX SA, H1 2017
Esophageal Cancer - Pipeline by Mebiopharm Co Ltd, H1 2017
Esophageal Cancer - Pipeline by MedImmune LLC, H1 2017
Esophageal Cancer - Pipeline by Merck & Co Inc, H1 2017
Esophageal Cancer - Pipeline by Novartis AG, H1 2017
Esophageal Cancer - Pipeline by Omeros Corp, H1 2017
Esophageal Cancer - Pipeline by Oncolys BioPharma Inc, H1 2017
Esophageal Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H1 2017
Esophageal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Esophageal Cancer - Pipeline by Puma Biotechnology Inc, H1 2017
Esophageal Cancer - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
Esophageal Cancer - Pipeline by Shionogi & Co Ltd, H1 2017
Esophageal Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
Esophageal Cancer - Pipeline by Stelic Institute & Co Inc, H1 2017
Esophageal Cancer - Pipeline by Supratek Pharma Inc, H1 2017
Esophageal Cancer - Pipeline by Symphogen A/S, H1 2017
Esophageal Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
Esophageal Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017
Esophageal Cancer - Pipeline by Takara Bio Inc, H1 2017
Esophageal Cancer - Pipeline by Transgene Biotek Ltd, H1 2017
Esophageal Cancer - Pipeline by VioQuest Pharmaceuticals Inc, H1 2017
Esophageal Cancer - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
Esophageal Cancer - Dormant Projects, H1 2017
Esophageal Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
Esophageal Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
Esophageal Cancer - Discontinued Products, H1 2017